Sparian Pipeline
Arylepoxamide Receptor (AEAr) Agonists
Acute and Chronic Pain
MOR/DOR Modulators
Opioid Use Disorder
Irreversible MOR Antagonists
Opioid Overdose
Peripheral DOR Bitopic Agonists
Neuropathic Pain
Discovery
Lead Optimization
CMC/IND Enabling Studies
Phase 1
SBS-1000 IV/SC
SBS-1001 Oral
SBS-226 Oral
SBS-371 IV/SC
SBS-406
AEAr Agonists
SBS-1000 IND-enabling Studies
SBS-1001 Lead Optimization
Acute and Chronic Pain
Arylepoxamides are first in class compounds which bind to the newly discovered receptor, the AEAr. In preclinical studies, arylepoxamides demonstrate potent analgesia for acute and chronic pain and a clean safety profile lacking respiratory depression, physical dependence, and reward behavior.
MOR Agonist/
DOR Antagonist
SBS-226 Lead Optimization
Opioid Use Disorder
Our MOR Agonist/DOR Antagonists are synthetic compounds that are structurally similar to mitragynine pseudoindoxyl - one of the primary alkaloids in Kratom. SBS-226 is a new chemical entity (NCE) synthesized and developed in the Majumdar Lab. SBS-226 is a very weak MOR agonist and potent DOR antagonist. Preclinically, SBS-226 can ameliorate opioid withdrawal but does not demonstrate abuse potential, respiratory depression, or physical dependence.
Irreversible MOR Antagonists
SBS-371 Lead Optimization
Opioid Overdose
SBS-371 is a first in class irreversible MOR antagonist being developed for the acute treatment and prophylaxis of opioid overdose. The opioid epidemic has transformed to a fentanyl epidemic and urgently demands more potent, longer lasting MOR antagonists. Preclinically, SBS-371 can prevent and reverse a synthetic opioid overdose (e.g. fentanyl and fentanyl derivatives).
Peripheral DOR Bitopic Agonists
SBS-406 Discovery
Neuropathic Pain
Our peripherally acting bitopic DOR agonists bind to the orthostatic and allosteric sites of delta opioid receptors (DOR). Preclinically, SBS-406 alleviates neuropathic pain and does not elicit the side effects seen with centrally acting DOR agonists.
